A case of immune complex type hemolytic anemia induced by initial micafungin administration

Hiroto Ishii; Tomohiko Sato; Miyuki Ishibashi; Hiroki Yokoyama; Takeshi Saito; Tetsunori Tasaki; Shingo Yano

doi:10.1016/j.ijid.2022.07.023

A case of immune complex type hemolytic anemia induced by initial micafungin administration

Int J Infect Dis. 2022 Sep:122:755-757. doi: 10.1016/j.ijid.2022.07.023. Epub 2022 Jul 15.

Authors

Hiroto Ishii¹, Tomohiko Sato², Miyuki Ishibashi², Hiroki Yokoyama³, Takeshi Saito³, Tetsunori Tasaki², Shingo Yano³

Affiliations

¹ Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. Electronic address: h-ishii@jikei.ac.jp.
² Division of Transfusion Medicine and Cell Therapy, The Jikei University Hospital, Tokyo, Japan.
³ Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

PMID: 35840096
DOI: 10.1016/j.ijid.2022.07.023

Abstract

We report the first case of immune complex type hemolytic anemia by initial micafungin administration that was given as prophylaxis to a 42-year-old Japanese man receiving chemotherapy for primary amyloidosis. The few cases found in the literature were associated with secondary administration causing immune hemolytic attacks. Despite its rarity, the present case calls for increased awareness of micafungin-induced hemolytic anemia upon initial administration.

Keywords: Drug-induced immune hemolytic anemia; Micafungin.

Publication types

Case Reports

MeSH terms

Adult
Anemia, Hemolytic* / chemically induced
Antigen-Antibody Complex* / adverse effects
Humans
Male
Micafungin / adverse effects

Substances

Antigen-Antibody Complex
Micafungin